Mouse models in oncoimmunology.
Identifieur interne : 001A91 ( Main/Exploration ); précédent : 001A90; suivant : 001A92Mouse models in oncoimmunology.
Auteurs : Laurence Zitvogel [France] ; Jonathan M. Pitt [France] ; Romain Daillère [France] ; Mark J. Smyth [Australie] ; Guido Kroemer [France]Source :
- Nature reviews. Cancer [ 1474-1768 ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
- immunologie : Tumeurs.
- physiopathologie : Système immunitaire.
- toxicité : Cancérogènes.
- traitement médicamenteux : Tumeurs.
- Alternatives à l'expérimentation animale, Animaux, Humains, Hétérogreffes, Modèles animaux de maladie humaine, Souris, Souris transgéniques, Tumeurs.
English descriptors
- KwdEn :
- MESH :
- chemical , toxicity : Carcinogens.
- chemically induced : Neoplasms.
- drug therapy : Neoplasms.
- immunology : Neoplasms.
- physiopathology : Immune System.
- Animal Testing Alternatives, Animals, Disease Models, Animal, Heterografts, Humans, Mice, Mice, Transgenic.
Abstract
Fundamental cancer research and the development of efficacious antineoplastic treatments both rely on experimental systems in which the relationship between malignant cells and immune cells can be studied. Mouse models of transplantable, carcinogen-induced or genetically engineered malignancies - each with their specific advantages and difficulties - have laid the foundations of oncoimmunology. These models have guided the immunosurveillance theory that postulates that evasion from immune control is an essential feature of cancer, the concept that the long-term effects of conventional cancer treatments mostly rely on the reinstatement of anticancer immune responses and the preclinical development of immunotherapies, including currently approved immune checkpoint blockers. Specific aspects of pharmacological development, as well as attempts to personalize cancer treatments using patient-derived xenografts, require the development of mouse models in which murine genes and cells are replaced with their human equivalents. Such 'humanized' mouse models are being progressively refined to characterize the leukocyte subpopulations that belong to the innate and acquired arms of the immune system as they infiltrate human cancers that are subjected to experimental therapies. We surmise that the ever-advancing refinement of murine preclinical models will accelerate the pace of therapeutic optimization in patients.
DOI: 10.1038/nrc.2016.91
PubMed: 27687979
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001434
- to stream PubMed, to step Curation: 001412
- to stream PubMed, to step Checkpoint: 001412
- to stream Ncbi, to step Merge: 003C37
- to stream Ncbi, to step Curation: 003C37
- to stream Ncbi, to step Checkpoint: 003C37
- to stream Main, to step Merge: 001A87
- to stream Main, to step Curation: 001A91
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mouse models in oncoimmunology.</title><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif</wicri:regionArea><wicri:noRegion>94805 Villejuif</wicri:noRegion><wicri:noRegion>94805 Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Pitt, Jonathan M" sort="Pitt, Jonathan M" uniqKey="Pitt J" first="Jonathan M" last="Pitt">Jonathan M. Pitt</name><affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif</wicri:regionArea><wicri:noRegion>94805 Villejuif</wicri:noRegion><wicri:noRegion>94805 Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Daillere, Romain" sort="Daillere, Romain" uniqKey="Daillere R" first="Romain" last="Daillère">Romain Daillère</name><affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif</wicri:regionArea><wicri:noRegion>94805 Villejuif</wicri:noRegion><wicri:noRegion>94805 Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><nlm:affiliation>QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; University of Queensland, Herston, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; University of Queensland, Herston, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation wicri:level="1"><nlm:affiliation>Equipe 11 labelisée par la Ligue Nationale contre le Cancer, INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Equipe 11 labelisée par la Ligue Nationale contre le Cancer, INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris</wicri:regionArea><wicri:noRegion>75006 Paris</wicri:noRegion><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27687979</idno><idno type="pmid">27687979</idno><idno type="doi">10.1038/nrc.2016.91</idno><idno type="wicri:Area/PubMed/Corpus">001434</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001434</idno><idno type="wicri:Area/PubMed/Curation">001412</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001412</idno><idno type="wicri:Area/PubMed/Checkpoint">001412</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001412</idno><idno type="wicri:Area/Ncbi/Merge">003C37</idno><idno type="wicri:Area/Ncbi/Curation">003C37</idno><idno type="wicri:Area/Ncbi/Checkpoint">003C37</idno><idno type="wicri:Area/Main/Merge">001A87</idno><idno type="wicri:Area/Main/Curation">001A91</idno><idno type="wicri:Area/Main/Exploration">001A91</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Mouse models in oncoimmunology.</title><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation wicri:level="3"><nlm:affiliation>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Villejuif</settlement></placeName></affiliation></author><author><name sortKey="Pitt, Jonathan M" sort="Pitt, Jonathan M" uniqKey="Pitt J" first="Jonathan M" last="Pitt">Jonathan M. Pitt</name><affiliation wicri:level="3"><nlm:affiliation>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Villejuif</settlement></placeName></affiliation></author><author><name sortKey="Daillere, Romain" sort="Daillere, Romain" uniqKey="Daillere R" first="Romain" last="Daillère">Romain Daillère</name><affiliation wicri:level="3"><nlm:affiliation>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Villejuif</settlement></placeName></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><nlm:affiliation>QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; University of Queensland, Herston, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; University of Queensland, Herston, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation wicri:level="1"><nlm:affiliation>Equipe 11 labelisée par la Ligue Nationale contre le Cancer, INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Equipe 11 labelisée par la Ligue Nationale contre le Cancer, INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris</wicri:regionArea><wicri:noRegion>75006 Paris</wicri:noRegion><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName></affiliation></author></analytic><series><title level="j">Nature reviews. Cancer</title><idno type="eISSN">1474-1768</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal Testing Alternatives</term><term>Animals</term><term>Carcinogens (toxicity)</term><term>Disease Models, Animal</term><term>Heterografts</term><term>Humans</term><term>Immune System (physiopathology)</term><term>Mice</term><term>Mice, Transgenic</term><term>Neoplasms (chemically induced)</term><term>Neoplasms (drug therapy)</term><term>Neoplasms (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Alternatives à l'expérimentation animale</term><term>Animaux</term><term>Cancérogènes (toxicité)</term><term>Humains</term><term>Hétérogreffes</term><term>Modèles animaux de maladie humaine</term><term>Souris</term><term>Souris transgéniques</term><term>Système immunitaire (physiopathologie)</term><term>Tumeurs ()</term><term>Tumeurs (immunologie)</term><term>Tumeurs (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Carcinogens</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Système immunitaire</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Immune System</term></keywords><keywords scheme="MESH" qualifier="toxicité" xml:lang="fr"><term>Cancérogènes</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animal Testing Alternatives</term><term>Animals</term><term>Disease Models, Animal</term><term>Heterografts</term><term>Humans</term><term>Mice</term><term>Mice, Transgenic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Alternatives à l'expérimentation animale</term><term>Animaux</term><term>Humains</term><term>Hétérogreffes</term><term>Modèles animaux de maladie humaine</term><term>Souris</term><term>Souris transgéniques</term><term>Tumeurs</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Fundamental cancer research and the development of efficacious antineoplastic treatments both rely on experimental systems in which the relationship between malignant cells and immune cells can be studied. Mouse models of transplantable, carcinogen-induced or genetically engineered malignancies - each with their specific advantages and difficulties - have laid the foundations of oncoimmunology. These models have guided the immunosurveillance theory that postulates that evasion from immune control is an essential feature of cancer, the concept that the long-term effects of conventional cancer treatments mostly rely on the reinstatement of anticancer immune responses and the preclinical development of immunotherapies, including currently approved immune checkpoint blockers. Specific aspects of pharmacological development, as well as attempts to personalize cancer treatments using patient-derived xenografts, require the development of mouse models in which murine genes and cells are replaced with their human equivalents. Such 'humanized' mouse models are being progressively refined to characterize the leukocyte subpopulations that belong to the innate and acquired arms of the immune system as they infiltrate human cancers that are subjected to experimental therapies. We surmise that the ever-advancing refinement of murine preclinical models will accelerate the pace of therapeutic optimization in patients.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li><li>Villejuif</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name></region><name sortKey="Daillere, Romain" sort="Daillere, Romain" uniqKey="Daillere R" first="Romain" last="Daillère">Romain Daillère</name><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><name sortKey="Pitt, Jonathan M" sort="Pitt, Jonathan M" uniqKey="Pitt J" first="Jonathan M" last="Pitt">Jonathan M. Pitt</name></country><country name="Australie"><noRegion><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A91 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A91 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27687979
|texte= Mouse models in oncoimmunology.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27687979" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |